Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC

Inclusion Criteria: histologic or cytologic diagnosis of NSCLC Presence of clinical Stage IIA,IIB or IIA disease tumor amenable to curative surgical resection Patients with clinically measurable lesions will be enrolled in this study. No prior tumor therapy Performance status of 0-1 on ECOG Scale Patients compliance and geographic proximity that allow adequate follow-up. Medical fitness of patient, including respiratory function, adequate for radical NSCLC surgery. Exclusion Criteria: Presence of clinical Stage IIIA disease, according to the revision by Mountain CF of American Joint Committee on Cancer. Treatment within the last 30 days with any investigational drug. Cocurrent administration of any other tumor therapy, including radiotherapy, cytotoxic chemotherapy, immunotherapy, molecular target therapy. Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy. pregnancy/breast feeding Serious concomitant disorders that would compromise the safety of the patient or compromise the patients ability to complete the study, at the discretion of the investigator. poorly controlled diabetes mellitus Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. History of significant neurological or mental disorder, including seizures or dementia.